July 15 (Reuters) - British drugmaker AstraZeneca Plc said on Monday the U.S. Food and Drug Administration declined to approve its diabetes treatment, Farxiga, for use as a supplement to insulin in adults with Type-1 diabetes.
The company said the regulator had issued a complete response letter, declining its application for using Farxiga in the new indication.
Farxiga is already approved in the United States for use in Type-2 diabetes. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)
Our Standards: The Thomson Reuters Trust Principles.